{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T02:16:05Z","timestamp":1781057765968,"version":"3.54.1"},"reference-count":36,"publisher":"China Science Publishing & Media Ltd.","issue":"3","funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["engine.scichina.com"],"crossmark-restriction":false},"short-container-title":["ABBS"],"published-print":{"date-parts":[[2018,3,1]]},"DOI":"10.1093\/abbs\/gmy004","type":"journal-article","created":{"date-parts":[[2018,1,7]],"date-time":"2018-01-07T12:08:22Z","timestamp":1515326902000},"page":"238-245","update-policy":"https:\/\/doi.org\/10.1360\/scp-crossmark-policy-page","source":"Crossref","is-referenced-by-count":13,"title":["C-reactive protein is associated with the development of tongue squamous cell carcinoma"],"prefix":"10.3724","volume":"50","author":[{"given":"Jianxin","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengzhe","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yegang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pishan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2026","published-online":{"date-parts":[[2018,3,1]]},"reference":[{"key":"null","doi-asserted-by":"crossref","first-page":"126","DOI":"10.2174\/1874210601206010126","volume":"6","author":"Markopoulos AK","year":"2012","unstructured":"Markopoulos AK. Current aspects on oral squamous cell carcinoma. Open Dent J, 2012, 6: 126-130.","journal-title":"Open Dent J"},{"key":"null","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"Siegel RL","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin, 2017, 67: 7-30.","journal-title":"CA Cancer J Clin"},{"key":"null","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1586\/14737140.6.7.1111","volume":"6","author":"Chin D","year":"2006","unstructured":"Chin D, Boyle GM, Porceddu S, Theile DR, Parsons PG, Coman WB. Head and neck cancer: past, present and future. Expert Rev Anticancer Ther, 2006, 6: 1111-1118.","journal-title":"Expert Rev Anticancer Ther"},{"key":"null","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/hed.20830","volume":"30","author":"Hamakawa H","year":"2008","unstructured":"Hamakawa H, Nakashiro K, Sumida T, Shintani S, Myers JN, Takes RP, Rinaldo A. Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer. Head Neck, 2008, 30: 800-809.","journal-title":"Head Neck"},{"key":"null","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","volume":"140","author":"Grivennikov SI","year":"2010","unstructured":"Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell, 2010, 140: 883-899.","journal-title":"Cell"},{"key":"null","first-page":"207","volume":"27","author":"Lotfi A","year":"2015","unstructured":"Lotfi A, Shahidi N, Bayazian G, AbdollahiFakhim S, Estakhri R, Esfahani A, Notash R. Serum level of interleukin-6 in patients with oral tongue squamous cell carcinoma. Iran J Otorhinolaryngol, 2015, 27: 207-211.","journal-title":"Iran J Otorhinolaryngol"},{"key":"null","doi-asserted-by":"crossref","first-page":"e0132677","DOI":"10.1371\/journal.pone.0132677","volume":"10","author":"Sun Y","year":"2015","unstructured":"Sun Y, Zhu D, Wang G, Wang D, Zhou H, Liu X, Jiang M. Pro-inflammatory cytokine IL-1 beta up-regulates CXC chemokine receptor 4 via notch and erk signaling pathways in tongue squamous cell carcinoma. PLoS One, 2015, 10:","journal-title":"PLoS One"},{"key":"null","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1200\/JCO.2007.11.2136","volume":"25","author":"Harrison ML","year":"2007","unstructured":"Harrison ML, Obermueller E, Maisey NR, Hoare S, Edmonds K, Li NF, Chao D. Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J Clin Oncol, 2007, 25: 4542-4549.","journal-title":"J Clin Oncol"},{"key":"null","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1172\/JCI200318921","volume":"111","author":"Pepys MB","year":"2003","unstructured":"Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest, 2003, 111: 1805-1812.","journal-title":"J Clin Invest"},{"key":"null","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.mehy.2003.12.014","volume":"62","author":"Li JJ","year":"2004","unstructured":"Li JJ, Fang CH. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases. Med Hypotheses, 2004, 62: 499-506.","journal-title":"Med Hypotheses"},{"key":"null","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1084\/jem.190.12.1733","volume":"190","author":"Griselli M","year":"1999","unstructured":"Griselli M, Herbert J, Hutchinson WL, Taylor KM, Sohail M, Krausz T, Pepys MB. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med, 1999, 190: 1733-1740.","journal-title":"J Exp Med"},{"key":"null","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jbmr.2037","volume":"29","author":"Eriksson AL","year":"2014","unstructured":"Eriksson AL, Moverare-Skrtic S, Ljunggren O, Karlsson M, Mellstrom D, Ohlsson C. High-sensitivity CRP is an independent risk factor for all fractures and vertebral fractures in elderly men: the MrOS Sweden study. J Bone Miner Res, 2014, 29: 418-423.","journal-title":"J Bone Miner Res"},{"key":"null","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cyto.2009.09.010","volume":"49","author":"Miyake K","year":"2010","unstructured":"Miyake K, Imura S, Nishioka M, Batmunkh E, Sugimoto K, Ohmoto Y, Shimada M. Serum evaluation of soluble interferon-alpha\/beta receptor and high-sensitivity C-reactive protein for diagnosis of the patients with gastrointestinal and hepatobiliary-pancreatic cancer. Cytokine, 2010, 49: 251-255.","journal-title":"Cytokine"},{"key":"null","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/15321819.2015.1132229","volume":"37","author":"Omran MM","year":"2016","unstructured":"Omran MM, Emran TM, Farid K, Eltaweel FM, Omar MA, Bazeed FB. An easy and useful noninvasive score based on alpha-1-acid glycoprotein and C-reactive protein for diagnosis of patients with hepatocellular carcinoma associated with hepatitis C virus infection. J Immunoassay Immunochem, 2016, 37: 273-288.","journal-title":"J Immunoassay Immunochem"},{"key":"null","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.jtcvs.2011.07.021","volume":"142","author":"Alifano M","year":"2011","unstructured":"Alifano M, Falcoz PE, Seegers V, Roche N, Schussler O, Younes M, Antonacci F. Preresection serum C-reactive protein measurement and survival among patients with resectable non-small cell lung cancer. J Thorac Cardiovasc Surg, 2011, 142: 1161-1167.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"null","first-page":"180","volume":"9","author":"Abdollahi A","year":"2015","unstructured":"Abdollahi A, Ali-Bakhshi A, Farahani Z. Concentration study of high sensitive C-reactive protein and some serum trace elements in patients with benign and malignant breast tumor. Int J Hematol Oncol Stem Cell Res, 2015, 9: 180-184.","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"key":"null","first-page":"471","volume":"32","author":"Wang CS","year":"2009","unstructured":"Wang CS, Sun CF. C-reactive protein and malignancy: clinico-pathological association and therapeutic implication. Chang Gung Med J, 2009, 32: 471-482.","journal-title":"Chang Gung Med J"},{"key":"null","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.lungcan.2008.04.011","volume":"63","author":"Lee JG","year":"2009","unstructured":"Lee JG, Cho BC, Bae MK, Lee CY, Park IK, Kim DJ, Ahn SV. Preoperative C-reactive protein levels are associated with tumor size and lymphovascular invasion in resected non-small cell lung cancer. Lung Cancer, 2009, 63: 106-110.","journal-title":"Lung Cancer"},{"key":"null","doi-asserted-by":"crossref","first-page":"e0143080","DOI":"10.1371\/journal.pone.0143080","volume":"10","author":"Shrotriya S","year":"2015","unstructured":"Shrotriya S, Walsh D, Bennani-Baiti N, Thomas S, Lorton C. C-reactive protein is an important biomarker for prognosis tumor recurrence and treatment response in adult solid tumors: a systematic review. PLoS One, 2015, 10:","journal-title":"PLoS One"},{"key":"null","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.pan.2015.09.016","volume":"15","author":"Kishi T","year":"2015","unstructured":"Kishi T, Nakamura A, Itasaka S, Shibuya K, Matsumoto S, Kanai M, Kodama Y. Pretreatment C-reactive protein level predicts outcome and patterns of failure after chemoradiotherapy for locally advanced pancreatic cancer. Pancreatology, 2015, 15: 694-700.","journal-title":"Pancreatology"},{"key":"null","first-page":"995","volume":"36","author":"Shibutani M","year":"2016","unstructured":"Shibutani M, Maeda K, Nagahara H, Iseki Y, Ikeya T, Hirakawa K. Prognostic significance of the preoperative ratio of C-reactive protein to albumin in patients with colorectal cancer. Anticancer Res, 2016, 36: 995-1001.","journal-title":"Anticancer Res"},{"key":"null","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.3892\/mco.2015.624","volume":"3","author":"Tang Z","year":"2015","unstructured":"Tang Z, Sheng H, Zheng X, Ying L, Wu L, Liu D, Liu G. Upregulation of circulating cytokeratin 20, urokinase plasminogen activator and C-reactive protein is associated with poor prognosis in gastric cancer. Mol Clin Oncol, 2015, 3: 1213-1220.","journal-title":"Mol Clin Oncol"},{"key":"null","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s10549-015-3671-1","volume":"155","author":"Frydenberg H","year":"2016","unstructured":"Frydenberg H, Thune I, Lofterod T, Mortensen ES, Eggen AE, Risberg T, Wist EA. Pre-diagnostic high-sensitive C-reactive protein and breast cancer risk, recurrence, and survival. Breast Cancer Res Treat, 2016, 155: 345-354.","journal-title":"Breast Cancer Res Treat"},{"key":"null","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ccr.2007.08.008","volume":"12","author":"Yang J","year":"2007","unstructured":"Yang J, Wezeman M, Zhang X, Lin P, Wang M, Qian J, Wan B. Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis. Cancer Cell, 2007, 12: 252-265.","journal-title":"Cancer Cell"},{"key":"null","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/eji.200738002","volume":"38","author":"Tron K","year":"2008","unstructured":"Tron K, Manolov DE, Rocker C, Kachele M, Torzewski J, Nienhaus GU. C-reactive protein specifically binds to Fcgamma receptor type I on a macrophage-like cell line. Eur J Immunol, 2008, 38: 1414-1422.","journal-title":"Eur J Immunol"},{"key":"null","doi-asserted-by":"crossref","first-page":"4974","DOI":"10.1073\/pnas.1018369108","volume":"108","author":"Lu J","year":"2011","unstructured":"Lu J, Marjon KD, Marnell LL, Wang R, Mold C, Du Clos TW, Sun P. Recognition and functional activation of the human IgA receptor (FcalphaRI) by C-reactive protein. Proc Natl Acad Sci U S A, 2011, 108: 4974-4979.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"null","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","volume":"420","author":"Coussens LM","year":"2002","unstructured":"Coussens LM, Werb Z. Inflammation and cancer. Nature, 2002, 420: 860-867.","journal-title":"Nature"},{"key":"null","doi-asserted-by":"crossref","first-page":"145647","DOI":"10.1155\/2015\/145647","volume":"2015","author":"Asegaonkar SB","year":"2015","unstructured":"Asegaonkar SB, Asegaonkar BN, Takalkar UV, Advani S, Thorat AP. C-reactive protein and breast cancer: new insights from old molecule. Int J Breast Cancer, 2015, 2015:","journal-title":"Int J Breast Cancer"},{"key":"null","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3892\/ijo.2016.3653","volume":"49","author":"Tanaka T","year":"2016","unstructured":"Tanaka T, Imamura T, Yoneda M, Irie A, Ogi H, Nagata M, Yoshida R. Enhancement of active MMP release and invasive activity of lymph node metastatic tongue cancer cells by elevated signaling via the TNF-alpha-TNFR1-NF-kappaB pathway and a possible involvement of angiopoietin-like 4 in lung metastasis. Int J Oncol, 2016, 49: 1377-1384.","journal-title":"Int J Oncol"},{"key":"null","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1038\/onc.2013.319","volume":"33","author":"Kim ES","year":"2014","unstructured":"Kim ES, Cha Y, Ham M, Jung J, Kim SG, Hwang S, Kleemann R. Inflammatory lipid sphingosine-1-phosphate upregulates C-reactive protein via C\/EBP beta and potentiates breast cancer progression. Oncogene, 2014, 33: 3583-3593.","journal-title":"Oncogene"},{"key":"null","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pharmthera.2014.09.006","volume":"146","author":"Bauer TM","year":"2015","unstructured":"Bauer TM, Patel MR, Infante JR. Targeting PI3 kinase in cancer. Pharmacol Ther, 2015, 146: 53-60.","journal-title":"Pharmacol Ther"},{"key":"null","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2044-5040-1-4","volume":"1","author":"Schiaffino S","year":"2011","unstructured":"Schiaffino S, Mammucari C. Regulation of skeletal muscle growth by the IGF1-Akt\/PKB pathway: insights from genetic models. Skelet Muscle, 2011, 1:","journal-title":"Skelet Muscle"},{"key":"null","doi-asserted-by":"crossref","first-page":"5856","DOI":"10.1158\/1078-0432.CCR-12-0662","volume":"18","author":"Slomovitz BM","year":"2012","unstructured":"Slomovitz BM, Coleman RL. The PI3K\/AKT\/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res, 2012, 18: 5856-5864.","journal-title":"Clin Cancer Res"},{"key":"null","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","volume":"12","author":"Guertin DA","year":"2007","unstructured":"Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell, 2007, 12: 9-22.","journal-title":"Cancer Cell"},{"key":"null","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/nrd1902","volume":"4","author":"Hennessy BT","year":"2005","unstructured":"Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K\/AKT pathway for cancer drug discovery. Nat Rev Drug Discov, 2005, 4: 988-1004.","journal-title":"Nat Rev Drug Discov"},{"key":"null","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/cdd.2011.98","volume":"19","author":"Kato H","year":"2012","unstructured":"Kato H, Nakajima S, Saito Y, Takahashi S, Katoh R, Kitamura M. mTORC1 serves ER stress-triggered apoptosis via selective activation of the IRE1-JNK pathway. Cell Death Differ, 2012, 19: 310-320.","journal-title":"Cell Death Differ"}],"container-title":["Acta Biochimica et Biophysica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/engine.scichina.com\/doi\/pdf\/BCEB3269AA804547816E56D5FFBC1CB4","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/engine.scichina.com\/doi\/10.1093\/abbs\/gmy004","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/engine.scichina.com\/doi\/pdf\/BCEB3269AA804547816E56D5FFBC1CB4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T22:55:02Z","timestamp":1660258502000},"score":1,"resource":{"primary":{"URL":"http:\/\/engine.scichina.com\/doi\/10.1093\/abbs\/gmy004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,1]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,3,1]]},"published-print":{"date-parts":[[2018,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/abbs\/gmy004","relation":{},"ISSN":["1672-9145"],"issn-type":[{"value":"1672-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3,1]]}}}